Top 3 Trends Impacting the Global Autoimmune and Inflammatory Immunomodulators Market Through 2020: Technavio

LONDON--()--Technavio’s latest report on the global autoimmune and inflammatory immunomodulators market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.

Sapna Jha, a lead analyst from Technavio, specializing in research on cardiovascular and metabolic disorders sector, says, “The global autoimmune and inflammatory immunomodulators market is expected to witness steady growth during the forecast period with a CAGR of approximately 7%. This growth is primarily credited to the increased uptake of biologics and entry of more efficacious and convenient products that will command greater value as compared to the therapies already present in the market.”

Request a sample report: http://www.technavio.com/request-a-sample?report=54329

Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.

The top three emerging trends driving the global autoimmune and inflammatory immunomodulators market according to Technavio healthcare and life sciences research analysts are:

  • Emergence of oral agents likely to improve patient outcomes
  • Advent of biosimilars expected to improve treatment rates
  • Focus on regenerative medicines

Emergence of oral agents likely to improve patient outcomes

The advent of oral agents in the treatment of rheumatoid arthritis and inflammatory bowel disease (IBD) is expected to have a positive impact on the market growth. For instance, Janus kinase (JAK) inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug.

Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel market growth. In addition, there are many oral agents in the pipeline, which are likely to have a positive impact on the growth of the market in the future.

Advent of biosimilars expected to improve treatment rates

The growing demand for quality care has led to the increased use of biologics for the treatment of inflammatory disorders such as rheumatoid arthritis and IBD. Countries worldwide are under pressure to address this demand without increasing healthcare expenditure. Biosimilars are likely to play a significant role in this scenario, as, unlike generic drugs, they have identical active pharmaceutical ingredients to their originator biologic compounds. Biosimilars are less expensive than biologics, thereby increasing accessibility. The patent expiry of biologics has led to the emergence of their biosimilars such as Inflectra (Remicade) and ABP 501 (Humira).

In April 2016, the US FDA approved Inflectra (Remicade biosimilar version), the first biosimilar approved for the treatment of rheumatoid arthritis and IBD. Inflectra will reduce the cost of rheumatoid arthritis treatments by 71%. Similarly, ABP 501, a Humira biosimilar, is undergoing Phase III trials and is expected to enter the market during the forecast period.

Focus on regenerative medicines

The use of regenerative medicine is an emerging treatment option for the treatment of IBD and rheumatoid arthritis. These regenerative medicines help in the healing process by replacement or regeneration of human cells, tissues or organs, and thus assist in establishing normal function. Currently, the available treatment options help in reducing the inflammation and prevent immune responses, rather than providing a complete cure for the disease. Therefore, scientists are developing new treatment options that will be effective in the total remission of the disease.

Apart from the companies, many research institutions are also focusing on the development of cell therapies for the treatment of IBD and rheumatoid arthritis. For instance, researchers at Wake Forest School of Medicine Institute for Regenerative Medicine have identified a cord blood stem cell that migrates and proliferates in the intestine, thus restoring the structure and function of the intestine. Scientists are developing stem cells that have anti-inflammatory/immunomodulatory effects for the treatment of IBD. Similarly, Queenstown Regenerative Medicine has developed stem cell treatment for rheumatoid arthritis. Also, University of California is developing human embryonic stem cells as a treatment option for IBD patients. “These regenerative therapies, once approved will positively impact the market as they are expected to be more efficacious as compared to conventional therapies,” says Sapna.

Browse Related Reports:

Do you need a report on a market in a specific geographical cluster or country but can’t find what you’re looking for? Don’t worry, Technavio also takes client requests. Please contact enquiry@technavio.com with your requirements and our analysts will be happy to create a customized report just for you.

About Technavio

Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.

Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com

Release Summary

Technavio’s latest report on the global autoimmune and inflammatory immunomodulators market provides an analysis on the most important trends expected to impact the market outlook from 2016-2020.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 630 333 9501
UK: +44 208 123 1770
www.technavio.com